Your browser doesn't support javascript.
loading
A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.
Pisignano, Giuseppina; Napoli, Sara; Magistri, Marco; Mapelli, Sarah N; Pastori, Chiara; Di Marco, Stefano; Civenni, Gianluca; Albino, Domenico; Enriquez, Claudia; Allegrini, Sara; Mitra, Abhishek; D'Ambrosio, Gioacchino; Mello-Grand, Maurizia; Chiorino, Giovanna; Garcia-Escudero, Ramon; Varani, Gabriele; Carbone, Giuseppina M; Catapano, Carlo V.
Afiliação
  • Pisignano G; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Napoli S; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Magistri M; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Mapelli SN; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Pastori C; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Di Marco S; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Civenni G; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Albino D; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Enriquez C; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Allegrini S; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Mitra A; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • D'Ambrosio G; IRCCS Multimedica, Milan 20099, Italy.
  • Mello-Grand M; Laboratory of Cancer Genomics, Fondo Edo Tempia, Biella 13900, Italy.
  • Chiorino G; Laboratory of Cancer Genomics, Fondo Edo Tempia, Biella 13900, Italy.
  • Garcia-Escudero R; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Varani G; Molecular Oncology Unit, CIEMAT and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid 28040, Spain.
  • Carbone GM; Department of Chemistry, University of Washington, Seattle, Washington 98195-1700, USA.
  • Catapano CV; Tumor Biology and Experimental Therapeutics Program, Institute of Oncology Research (IOR), and Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
Nat Commun ; 8: 15622, 2017 05 30.
Article em En | MEDLINE | ID: mdl-28555645
Long noncoding RNAs are emerging players in the epigenetic machinery with key roles in development and diseases. Here we uncover a complex network comprising a promoter-associated noncoding RNA (paRNA), microRNA and epigenetic regulators that controls transcription of the tumour suppressor E-cadherin in epithelial cancers. E-cadherin silencing relies on the formation of a complex between the paRNA and microRNA-guided Argonaute 1 that, together, recruit SUV39H1 and induce repressive chromatin modifications in the gene promoter. A single nucleotide polymorphism (rs16260) linked to increased cancer risk alters the secondary structure of the paRNA, with the risk allele facilitating the assembly of the microRNA-guided Argonaute 1 complex and gene silencing. Collectively, these data demonstrate the role of a paRNA in E-cadherin regulation and the impact of a noncoding genetic variant on its function. Deregulation of paRNA-based epigenetic networks may contribute to cancer and other diseases making them promising targets for drug discovery.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Repressoras / Caderinas / Inativação Gênica / Fatores de Iniciação em Eucariotos / Proteínas Argonautas / Metiltransferases / Neoplasias Limite: Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Proteínas Repressoras / Caderinas / Inativação Gênica / Fatores de Iniciação em Eucariotos / Proteínas Argonautas / Metiltransferases / Neoplasias Limite: Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article